Drug intelligence / Profile preview

SCT-001 CAR-T cells

Development stage: Phase 1
Lead developer: Shanghai Gynecologic Oncology Group
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intraperitoneal, Intravenous

Overview

SCT-001 CAR-T cells is an investigational chimeric antigen receptor T-cell therapy being developed for the treatment of recurrent and refractory epithelial ovarian cancer, fallopian tube cancer, and peritoneal cancer. It is currently in Phase 1 clinical development, with a trial scheduled to begin in June 2025 to evaluate its safety, tolerability, and preliminary efficacy. The therapy will be administered through both intraperitoneal and intravenous routes.

Beyond the preview

Go deeper on SCT-001 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT-001 CAR-T cells.

Explore the full profile